Literature DB >> 14720612

Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval.

Jennifer Smit1, Julia Botha, Lynn McFadyen, Mags Beksinska.   

Abstract

In the absence of published data on serum medroxyprogesterone acetate (MPA) levels in South African users, this study examines such levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval. The study was undertaken at three family-planning clinics in Durban, South Africa. Serum MPA levels were measured in 94 Black African, Indian and White women returning between 11 and 14 weeks after their last injection. The median serum MPA level was 0.88 (range, <0.04-1.77) ng/mL and wide interindividual variability was observed. Levels in all but one woman were higher than 0.1 ng/mL, the level at which ovulation is reported to resume. MPA levels were not found to vary according to weight, body mass index or ethnicity. Although there was a slight tendency towards higher MPA levels with longer duration of use (r = 0.13), the wide interindividual variability precluded the possibility of determining whether this was a real trend. A prospective study, using standardized assay techniques and following individual women, is required to further clarify this issue.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14720612     DOI: 10.1016/j.contraception.2003.09.005

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial.

Authors:  D E Bonds; N Lasser; L Qi; R Brzyski; B Caan; G Heiss; M C Limacher; J H Liu; E Mason; A Oberman; M J O'Sullivan; L S Phillips; R J Prineas; L Tinker
Journal:  Diabetologia       Date:  2006-01-27       Impact factor: 10.122

3.  The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.

Authors:  Léanie Kleynhans; Nelita Du Plessis; Nasiema Allie; Muazzam Jacobs; Martin Kidd; Paul D van Helden; Gerhard Walzl; Katharina Ronacher
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

4.  A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females.

Authors:  Andrea E Bonny; Hannah L H Lange; Lynette K Rogers; Dave M Gothard; Michael D Reed
Journal:  Contraception       Date:  2014-02-01       Impact factor: 3.375

5.  Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Authors:  Chelsea B Polis; Sharon L Achilles; Zdenek Hel; Janet P Hapgood
Journal:  Contraception       Date:  2017-12-11       Impact factor: 3.375

6.  Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection.

Authors:  Rodolfo D Vicetti Miguel; Robert L Hendricks; Alfredo J Aguirre; Melissa A Melan; Stephen A K Harvey; Tracy Terry-Allison; Anthony J St Leger; Angus W Thomson; Thomas L Cherpes
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

Review 7.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

8.  Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency.

Authors:  Rosie Mngqibisa; Michelle A Kendall; Kelly Dooley; Xingye Shirley Wu; Cynthia Firnhaber; Helen Mcilleron; Jennifer Robinson; Yoninah Cramer; Susan L Rosenkranz; Jhoanna Roa; Kristine Coughlin; Sajeeda Mawlana; Sharlaa Badal-Faesen; David Schnabel; Ayotunde Omoz-Oarhe; Wadzanai Samaneka; Catherine Godfrey; Susan E Cohn
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 20.999

9.  Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.

Authors:  David W Haas; Rosie Mngqibisa; Jose Francis; Helen McIlleron; Jennifer A Robinson; Michelle A Kendall; Paxton Baker; Sajeeda Mawlana; Sharlaa Badal-Faesen; Francis Angira; Ayotunde Omoz-Oarhe; Wadzanai P Samaneka; Paolo Denti; Susan E Cohn
Journal:  Pharmacogenet Genomics       Date:  2022-01-01       Impact factor: 2.000

10.  Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.

Authors:  Kavita Nanda; Rebecca Callahan; Douglas Taylor; Meng Wang; Kawango Agot; David Jenkins; Lut Van Damme; Laneta Dorflinger
Journal:  Contraception       Date:  2016-03-10       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.